MedCity News March 6, 2025
Frank Vinluan

Jazz Pharmaceuticals’ acquisition of Chimerix brings a drug that could become the first approved therapy for a rare and aggressive form of brain cancer affecting children and young adults. An FDA decision for the molecule, dordaviprone, is expected in August.

Brain cancers are notoriously difficult to treat, with surgery and radiation continuing to be the main options for these malignancies. A rare and aggressive type of brain tumor driven by a particular genetic signature could soon have its first approved drug treatment. Jazz Pharmaceuticals is now committing $935 million to add this prospect to its pipeline.

The drug, dordaviprone, was developed by Durham, North Carolina-based Chimerix. The cancer is H3 K27M-mutant diffuse glioma, a high-grade glioma that affects children and...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Related Articles:
The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle
Will Trump Drug Tariffs Help Or Hurt The U.S.?
Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy
Walgreens To Be Acquired By PE Firm Sycamore Partners Amid Shift In Health Care Strategy
Medicare Coverage Of Medical Technologies In A New Era

Share This Article